<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">NCP</journal-id>
<journal-id journal-id-type="hwp">spncp</journal-id>
<journal-id journal-id-type="nlm-ta">Nutr Clin Pract</journal-id>
<journal-title>Nutrition in Clinical Practice</journal-title>
<issn pub-type="ppub">0884-5336</issn>
<issn pub-type="epub">1941-2452</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0884533612449654</article-id>
<article-id pub-id-type="publisher-id">10.1177_0884533612449654</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Clinical Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Higher Plasma Homocysteine Is Associated With Lower Vitamin B<sub>6</sub> Status in Critically Ill Surgical Patients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Hou</surname><given-names>Chen-Tai</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0884533612449654">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wu</surname><given-names>Ying-Hsun</given-names></name>
<degrees>MSc</degrees>
<xref ref-type="aff" rid="aff2-0884533612449654">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Cheng</surname><given-names>Chien-Hsiang</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff3-0884533612449654">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Huang</surname><given-names>Pei-Ning</given-names></name>
<degrees>MSc, RD</degrees>
<xref ref-type="aff" rid="aff4-0884533612449654">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Huang</surname><given-names>Yi-Chia</given-names></name>
<degrees>PhD, RD</degrees>
<xref ref-type="aff" rid="aff5-0884533612449654">5</xref>
</contrib>
</contrib-group>
<aff id="aff1-0884533612449654"><label>1</label>Critical Care, Changhua Christian Hospital, Changhua, Taiwan</aff>
<aff id="aff2-0884533612449654"><label>2</label>Burn Center, Changhua Cristian Hospital, Changhua, Taiwan</aff>
<aff id="aff3-0884533612449654"><label>3</label>Intensive Care Unit, Critical Care and Respiratory Therapy, Taichung Veterans General Hospital, and Department of Nursing, HungKuang University, Taichung, Taiwan</aff>
<aff id="aff4-0884533612449654"><label>4</label>Department of Nutrition, St Martin De Porres Hospital, Chia-Yi, Taiwan</aff>
<aff id="aff5-0884533612449654"><label>5</label>School of Nutrition, Chung Shan Medical University, and the Department of Nutrition, Chung Shan Medical University Hospital, Taichung, Taiwan</aff>
<author-notes>
<corresp id="corresp1-0884533612449654">Yi-Chia Huang, PhD, RD, Chung Shan Medical University, No. 110, Sec 1, Jianguo N. Rd. School of Nutrition, Taichung, ROC 402, Taiwan; e-mail: <email>ych@csmu.edu.tw</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>10</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>5</issue>
<issue-title>Nutrition and Cancer</issue-title>
<fpage>695</fpage>
<lpage>700</lpage>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Background</italic>: Hyperhomocysteinemia might be at least partially due to compromised B vitamin status in critically ill patients and has been linked with critical illness. This study was conducted to examine the association between plasma homocysteine with B vitamins and clinical outcomes in critically ill surgical patients. <italic>Methods</italic>: Thirty-two patients in the surgical intensive care unit (SICU) were enrolled. Disease severity (Acute Physiology and Chronic Health Evaluation II score), hematological values, serum and erythrocyte folate, serum vitamin B<sub>12</sub>, plasma, and erythrocyte pyridoxal 5′-phosphate (PLP) were determined within 24 hours of admission and again after 7 days. <italic>Results</italic>: The prevalence of hyperhomocysteinemia in the patients was either 46.9% (plasma homocysteine ≥12 µmol/L) or 31.3% (plasma homocysteine ≥15 µmol/L) on day 1 in the SICU and increased to 62.5% (plasma homocysteine ≥12 µmol/L) and 37.5% (plasma homocysteine ≥15 µmol/L) on day 7 after admission to the SICU. Plasma homocysteine, serum folate, and vitamin B<sub>12</sub> significantly increased by day 7, whereas plasma and erythrocyte PLP remained constant throughout the study. Plasma homocysteine was not correlated with serum folate and vitamin B<sub>12</sub>. However, plasma and erythrocyte PLP on day 1 were adversely associated with day 1 levels of plasma homocysteine after adjusting for potential confounders. Plasma homocysteine on day 1 or changes (Δ day 7 – day 1) did not show any association with clinical outcomes. <italic>Conclusions</italic>: Lower plasma PLP might be a significant factor for increased plasma homocysteine in critically ill surgical patients. The association between plasma homocysteine and clinical outcomes was not found.</p>
</abstract>
<kwd-group>
<kwd>hyperhomocysteinemia</kwd>
<kwd>vitamin B6</kwd>
<kwd>vitamin B12</kwd>
<kwd>folic acid</kwd>
<kwd>critical illness</kwd>
<kwd>intensive care</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Homocysteine, a sulfur-containing amino acid, is either remethylated to form methionine or transsulfurated to form cysteine.<sup><xref ref-type="bibr" rid="bibr1-0884533612449654">1</xref></sup> In the remethylation pathway, it requires folate as a cosubstrate and vitamin B<sub>12</sub> as a cofactor. When methionine is in excess, homocysteine is directed to the transsulfuration pathway, which requires pyridoxal 5′-phosphate (PLP), the physiologically active coenzyme form of vitamin B<sub>6</sub>, as a coenzyme.<sup><xref ref-type="bibr" rid="bibr1-0884533612449654">1</xref></sup> B vitamin deficiencies, therefore, are associated with mild to moderate hyperhomocysteinemia. Hyperhomocysteinemia, a well-known risk factor for cardiovascular disease,<sup><xref ref-type="bibr" rid="bibr2-0884533612449654">2</xref><xref ref-type="bibr" rid="bibr3-0884533612449654"/>-<xref ref-type="bibr" rid="bibr4-0884533612449654">4</xref></sup> can increase the overproduction of oxygen free radicals through homocysteine oxidation<sup><xref ref-type="bibr" rid="bibr5-0884533612449654">5</xref></sup> and has been shown to be associated with increased inflammatory markers (ie, interleukin-6, C-reactive protein).<sup><xref ref-type="bibr" rid="bibr6-0884533612449654">6</xref>,<xref ref-type="bibr" rid="bibr7-0884533612449654">7</xref></sup></p>
<p>Critically ill patients are susceptible to various insults during the acute phase of illness. They are at risk of stress and inflammation, resulting in increased catabolism. Stress, inflammation, and severity of illness may in turn increase the utilization and metabolic turnover of B vitamins (ie, vitamin B<sub>6</sub>, folate, and vitamin B<sub>12</sub>). Previous studies<sup><xref ref-type="bibr" rid="bibr8-0884533612449654">8</xref><xref ref-type="bibr" rid="bibr9-0884533612449654"/><xref ref-type="bibr" rid="bibr10-0884533612449654"/><xref ref-type="bibr" rid="bibr11-0884533612449654"/><xref ref-type="bibr" rid="bibr12-0884533612449654"/>-<xref ref-type="bibr" rid="bibr13-0884533612449654">13</xref></sup> have reported a lower status of B vitamins in hospitalized patients. Therefore, increased homocysteine levels might be at least partially due to compromised B vitamin status and further cause increased oxidative stress and inflammatory responses in critically ill patients. Schindler et al<sup><xref ref-type="bibr" rid="bibr14-0884533612449654">14</xref></sup> were the first researchers to provide evidence linking mild to moderate hyperhomocysteinemia with critical illness. However, they did not observe any association between plasma homocysteine and status of B vitamins, although they did report 86%, 16%, and 9% of vitamin B<sub>6</sub>, vitamin B<sub>12</sub>, and folate deficiencies in critically ill patients, respectively.<sup><xref ref-type="bibr" rid="bibr14-0884533612449654">14</xref></sup> On the other hand, Abilés et al<sup><xref ref-type="bibr" rid="bibr15-0884533612449654">15</xref></sup> indicated that adequate folate and vitamin B<sub>12</sub> intakes could reduce the risk of hyperhomocysteinemia in critically ill patients.</p>
<p>To date, there have been only a few reports on the status of B vitamins and homocysteine in surgical intensive care unit (SICU) patients. Therefore, the purpose of this study was to assess the association of plasma homocysteine with B vitamins in critically ill surgical patients. In addition, the association between plasma homocysteine concentration and clinical outcomes was examined.</p>
<sec id="section1-0884533612449654" sec-type="methods">
<title>Patients and Methods</title>
<sec id="section2-0884533612449654">
<title>Patients</title>
<p>The study was designed as an observational cross-sectional study. Patients were recruited at Changhua Christian Hospital, which is a teaching hospital in the central part of Taiwan. All patients admitted or transferred to the SICU were screened for potential study participation. Only patients who were assessed for the entire duration of the study and required a stay of at least 7 days in the SICU were included in the final analysis. Patients were excluded if they were uremic, clinically unstable (ie, systolic blood pressure &lt;90 mm Hg, mean arterial blood pressure &lt;65 mm Hg, fatal arrhythmia, or required vasopressors to maintain blood pressure), or unconscious at any point during the study. Medical records, including diagnoses, severity of illness (by using the Acute Physiology and Chronic Health Evaluation II [APACHE II] score), length of SICU and hospital stays, and ventilatory dependency, were obtained. Patients’ age, sex, height, weight, and APACHE II score on admission were assessed within 24 hours of admission and again after 7 days in the SICU. The study was approved by the Institutional Review Board of Changhua Christian Hospital. Informed consent was obtained from all patients or their legal relatives.</p>
</sec>
<sec id="section3-0884533612449654">
<title>B Vitamin Intake</title>
<p>All patients received nutrition support via enteral administration based on the physician’s recommendations. The tube-feeding formulas were prepared from various commercial products based on the patient’s nutrition needs. Folate, vitamin B<sub>6</sub>, and vitamin B<sub>12</sub> intakes from enteral nutrition (EN) and intravenous (IV) crystalloid infusions were recorded daily by the SICU nurses. The amount of nutrient intake represented in the results was the amount of feed delivered on days 1 and 7 and the 7-day average in the SICU. No multivitamin supplements were given to the patients during the study period.</p>
</sec>
<sec id="section4-0884533612449654">
<title>Biochemical Measurements</title>
<p>Fasting blood samples were drawn from SICU patients by venipuncture within 24 hours of admission and again after 7 days. Venous blood samples were collected in Vacutainer tubes (Becton Dickinson, Rutherford, NJ) containing an appropriate anticoagulant or no anticoagulant to determine serum albumin, hemoglobin, creatinine and C-reactive protein (CRP), plasma homocysteine, plasma and erythrocyte PLP, serum folate, and vitamin B<sub>12</sub> concentrations. Twenty-four-hour urine collections were obtained on days 1 and 7 in the SICU to measure patients’ urinary creatinine concentration, and urine volumes were determined and aliquots stored frozen (−20°C) until analysis. Patients’ renal function was assessed by calculating the creatinine clearance rate (CCR).</p>
<p>Automated CRP measurement concentration was performed using particle-enhanced immunonephelometry with an image analyzer. Plasma homocysteine was measured by using high-performance liquid chromatography (HPLC) with a modified method as described previously<sup><xref ref-type="bibr" rid="bibr16-0884533612449654">16</xref>,<xref ref-type="bibr" rid="bibr17-0884533612449654">17</xref></sup>; inter- and intra-assay variabilities were 5.12% (n = 12) and 3.82% (n = 5), respectively. Plasma and erythrocyte PLP were determined by HPLC using a method described by Talwar et al.<sup><xref ref-type="bibr" rid="bibr18-0884533612449654">18</xref></sup> The inter- and intra-assay variabilities were 2.14% (n = 15) and 1.65% (n = 3) for plasma PLP and 7.2% (n = 7) and 7.3% (n = 3) for erythrocyte PLP, respectively. Serum and erythrocyte folate and serum vitamin B<sub>12</sub> were analyzed using standard competitive immunochemiluminometric methods on a Chiron Diagnostics ACS:180 Automated Chemiluminescence Systems (Chiron Diagnostics Corporation, Emeryville, CA). Homocysteine and vitamin B<sub>6</sub> measurements were carried out under yellow light to prevent photodestruction. The major excretory metabolite of vitamin B<sub>6</sub>, urinary 4-pyridoxic acid (4-PA), was analyzed by HPLC using the modified method of Gregory and Kirk.<sup><xref ref-type="bibr" rid="bibr19-0884533612449654">19</xref></sup> All urine samples thawed for 4-PA determination were kept on ice to prevent lactonization of 4-PA.</p>
<p>Hyperhomocysteinemia was defined as a plasma homocysteine concentration ≥15 µmol/L or ≥12 µmol/L.<sup><xref ref-type="bibr" rid="bibr20-0884533612449654">20</xref></sup> Vitamin B<sub>12</sub> and folate deficiencies were defined as serum concentrations of &lt;125 pmol/L and 6.3 nmol/L, respectively.<sup><xref ref-type="bibr" rid="bibr21-0884533612449654">21</xref></sup> Vitamin B<sub>6</sub> deficiency was defined as plasma PLP concentration &lt;20 nmol/L and/or urinary 4-PA concentration &lt;3 µmol/d.<sup><xref ref-type="bibr" rid="bibr22-0884533612449654">22</xref></sup></p>
</sec>
<sec id="section5-0884533612449654">
<title>Statistical Analysis</title>
<p>Data were analyzed by using the SAS statistical software (version 9.2; SAS Institute, Cary, NC). Differences in patients’ anthropometric measurements and biochemical values were compared for significant differences between days 1 and 7 in the SICU using the paired <italic>t</italic> test or Wilcoxon signed rank test. Fisher’s exact test or the χ<sup>2</sup> test was used for the analysis of categorical variables, and Fisher’s exact test was used if the expected frequency &lt;5. Spearman partial correlation coefficient (<italic>r</italic><sub><italic>s</italic></sub>) was used to analyze correlations between the means of plasma homocysteine, B vitamins, and clinical outcomes after adjusting for the potential confounders. Results were considered statistically significant at <italic>P</italic> &lt; .05. Values presented in the text are means ± standard error (SE).</p>
</sec>
</sec>
<sec id="section6-0884533612449654" sec-type="results">
<title>Results</title>
<sec id="section7-0884533612449654">
<title>Characteristics of the Patients</title>
<p>Demographic characteristics of the SICU patients are shown in <xref ref-type="table" rid="table1-0884533612449654">Table 1</xref>. Of the 50 patients enrolled, 34 successfully completed the study. However, we accidentally lost 2 patients’ plasma homocysteine samples; therefore, only 32 patients’ data were analyzed in this study. Patients’ ages ranged from 20.7–89.1 years, with a median age of 64.5 years. There were no significant changes in CCR value and APACHE II score between days 1 and 7 after admission. Patients’ body weight significantly increased by day 7 compared with the value on day 1. The most common diagnoses of patients at the time of admission to the SICU were intracerebral hemorrhage, subarachnoid hemorrhage, cervical spine fracture, aortic dissection, and multiple traumas.</p>
<table-wrap id="table1-0884533612449654" position="float">
<label>Table 1.</label>
<caption><p>Characteristics of Critically Ill Patients on Days 1 and 7 of Admission to the Surgical Intensive Care Unit</p></caption>
<graphic alternate-form-of="table1-0884533612449654" xlink:href="10.1177_0884533612449654-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Characteristics</th>
<th align="center">Day 1 (n = 32)</th>
<th align="center">Day 7 (n = 32)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, male/female, No.</td>
<td align="center" colspan="2">15/17</td>
</tr>
<tr>
<td>Age, y</td>
<td align="center" colspan="2">62.56 ± 3.08</td>
</tr>
<tr>
<td>Body weight, kg</td>
<td>58.29 ± 1.92<sup><xref ref-type="table-fn" rid="table-fn2-0884533612449654">a</xref></sup></td>
<td>60.74 ± 1.95<sup><xref ref-type="table-fn" rid="table-fn2-0884533612449654">b</xref></sup></td>
</tr>
<tr>
<td>Creatinine clearance rate, mL/min</td>
<td>102. 3 ± 9.87</td>
<td>109.6 ± 12.04</td>
</tr>
<tr>
<td>APACHE II score</td>
<td>19.88 ± 1.02</td>
<td>17.94 ± 1.74</td>
</tr>
<tr>
<td>Length of ventilatory dependency, d</td>
<td align="center" colspan="2">16.72 ± 2.46</td>
</tr>
<tr>
<td>Length of SICU day, d</td>
<td align="center" colspan="2">17.19 ± 1.82</td>
</tr>
<tr>
<td>Length of hospital stay, d</td>
<td align="center" colspan="2">33.06 ± 4.02</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0884533612449654">
<p>Values are means ± standard error except where indicated otherwise. APACHE II, Acute Physiology and Chronic Health Evaluation II; SICU, surgical intensive care unit.</p>
</fn>
<fn id="table-fn2-0884533612449654">
<label>a,b</label>
<p>Values are significantly different between day 1 and day 7 within the group; <italic>P</italic> &lt; .05.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section8-0884533612449654">
<title>B Vitamin Intakes</title>
<p>Patients’ energy and protein intakes were 665.88 ± 91.81 kcal and 27.86 ± 3.84 g on day 1, respectively, and 1327.16 ± 83.16 kcal and 55.52 ± 3.48 g on day 7, respectively. The 7-day averages of energy and protein intake were 1131.29 ± 67.84 kcal and 55.64 ± 2.85 g, respectively. Folate, vitamin B<sub>6</sub>, and vitamin B<sub>12</sub> intakes on days 1 and 7 after admission to the SICU are shown in <xref ref-type="table" rid="table2-0884533612449654">Table 2</xref>. Patients had significantly higher folate, vitamin B<sub>6</sub>, and vitamin B<sub>12</sub> intakes on day 7 than on day 1 of admission. The mean folate, vitamin B<sub>6</sub>, and vitamin B<sub>12</sub> intakes on day 7 and the 7-day average were higher than the US Dietary Reference Intakes<sup><xref ref-type="bibr" rid="bibr21-0884533612449654">21</xref></sup> and the current Taiwan Dietary Reference Intakes (Department of Health, Taiwan, 2002).</p>
<table-wrap id="table2-0884533612449654" position="float">
<label>Table 2.</label>
<caption><p>Hematological Measurements, Homocysteine, Inflammatory Markers, and B Vitamins in Critically Ill Patients on Days 1 and 7 of Admission to the Intensive Care Unit</p></caption>
<graphic alternate-form-of="table2-0884533612449654" xlink:href="10.1177_0884533612449654-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Variables</th>
<th align="center">Day 1 (n = 32)</th>
<th align="center">Day 7 (n = 32)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum albumin, g/L</td>
<td>3.30 ± 0.10<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">a</xref></sup></td>
<td>2.82 ± 0.08<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">b</xref></sup></td>
</tr>
<tr>
<td>Hemoglobin, g/dL</td>
<td>11.98 ± 0.35<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">a</xref></sup></td>
<td>10.28 ± 0.35<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">b</xref></sup></td>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td>1.02 ± 0.13</td>
<td>1.02 ± 0.21</td>
</tr>
<tr>
<td>C-reactive protein, mg/L</td>
<td>0.89 ± 0.11</td>
<td>1.10 ± 0.14</td>
</tr>
<tr>
<td>Plasma homocysteine, µmol/L</td>
<td>12.45 ± 1.00<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">a</xref></sup></td>
<td>14.06 ± 0.74<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">b</xref></sup></td>
</tr>
<tr>
<td>Vitamin B<sub>6</sub> status</td>
<td/>
<td/>
</tr>
<tr>
<td> Plasma PLP, nmol/L</td>
<td>32.96 ± 5.37</td>
<td>33.36 ± 3.96</td>
</tr>
<tr>
<td>  &lt;20 nmol/L, No. (%)</td>
<td>14 (43.8)</td>
<td>9 (28.1)</td>
</tr>
<tr>
<td> Erythrocyte PLP, nmol/L</td>
<td>29.23 ± 3.12</td>
<td>25.42 ± 1.37</td>
</tr>
<tr>
<td> Erythrocyte PLP, pmol/g Hb</td>
<td>249.99 ± 26.91</td>
<td>257.14 ± 17.01</td>
</tr>
<tr>
<td> Urinary 4-PA, µmol/d</td>
<td>9.95 ± 1.58<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">a</xref></sup></td>
<td>13.45 ± 5.12<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">b</xref></sup></td>
</tr>
<tr>
<td>  &lt;3 µmol/d, No. (%)</td>
<td>8 (25)</td>
<td>0</td>
</tr>
<tr>
<td> Vitamin B<sub>6</sub> intake, mg/d</td>
<td>1.41 ± 0.20<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">a</xref></sup></td>
<td>2.91 ± 0.18<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">b</xref></sup></td>
</tr>
<tr>
<td>  7-d average</td>
<td colspan="2">2.91 ± 0.15</td>
</tr>
<tr>
<td>Folate status</td>
<td/>
<td/>
</tr>
<tr>
<td> Serum folate, nmol/L</td>
<td>15.69 ± 1.84<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">a</xref></sup></td>
<td>34.97 ± 10.41<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">b</xref></sup></td>
</tr>
<tr>
<td>  &lt;6.3 nmol/L, No. (%)</td>
<td>4 (12.5)</td>
<td>0</td>
</tr>
<tr>
<td> Erythrocyte folate, nmol/L</td>
<td>1243.96 ± 75.87<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">a</xref></sup></td>
<td>1618.87 ± 150.42<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">b</xref></sup></td>
</tr>
<tr>
<td> Erythrocyte folate, nmol/g Hb</td>
<td>10.95 ± 0.84<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">a</xref></sup></td>
<td>16.98 ± 1.92<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">b</xref></sup></td>
</tr>
<tr>
<td> Folate intake, µg/d</td>
<td>280.13 ± 39.65<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">a</xref></sup></td>
<td>576.34 ± 36.12<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">b</xref></sup></td>
</tr>
<tr>
<td>  7-d average</td>
<td colspan="2">577.58 ± 29.56</td>
</tr>
<tr>
<td>Vitamin B<sub>12</sub> status</td>
<td/>
<td/>
</tr>
<tr>
<td> Serum vitamin B<sub>12</sub>, pmol/L</td>
<td>496.98 ± 90.16<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">a</xref></sup></td>
<td>696.55 ± 86.93<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">b</xref></sup></td>
</tr>
<tr>
<td>  &lt;125 pmol/L, No.</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> Vitamin B<sub>12</sub> intake, µg/d</td>
<td>4.37 ± 0.62<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">a</xref></sup></td>
<td>8.99 ± 0.56<sup><xref ref-type="table-fn" rid="table-fn4-0884533612449654">b</xref></sup></td>
</tr>
<tr>
<td>  7-d average</td>
<td colspan="2">9.01 ± 046</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0884533612449654">
<p>Values are means ± standard error, except where indicated otherwise, and are the 7-day average of admission to the surgical intensive care unit. 4-PA, 4-pyridoxic acid; Hb, hemoglobin; PLP, pyridoxal 5′-phosphate.</p>
</fn>
<fn id="table-fn4-0884533612449654">
<label>a,b</label>
<p>Values are significantly different between day 1 and day 7; <italic>P</italic> &lt; .05.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section9-0884533612449654">
<title>Biochemical Measurements</title>
<p><xref ref-type="table" rid="table2-0884533612449654">Table 2</xref> lists the values of hematologic measurements, homocysteine, and B vitamins on days 1 and 7 after admission to the SICU. On day 7 in the SICU, patients showed a significant reduction in mean serum albumin and hemoglobin levels when compared with day 1. There was no significant difference in the levels of CRP between days 1 and 7 in the SICU. The CRP levels on average and individually were above 0.8 mg/dL on days 1 and 7 in the SICU, which indicates that patients were in the inflammatory phases.</p>
<p>Plasma homocysteine concentration significantly increased by day 7 compared with the value on day 1. The prevalence of hyperhomocysteinemia in our SICU patients was either 46.9% (plasma homocysteine concentration ≥12 µmol/L) or 31.3% (plasma homocysteine concentration ≥15 µmol/L) on day 1 in the SICU. The prevalence of hyperhomocysteinemia increased to 62.5% (plasma homocysteine concentration ≥12 µmol/L) and 37.5% (plasma homocysteine concentration ≥15 µmol/L) on day 7 after admission to the SICU. Although vitamin B<sub>6</sub> intake significantly increased by day 7 of admission, mean plasma and erythrocyte PLP concentrations did not significantly change between days 1 and 7 in the SICU. In our patient cohort, 43.8% and 28.1% had a plasma PLP level lower than the suggested value (&gt;20 nmol/L) on days 1 and 7 of admission, respectively. Urinary 4-PA level significantly increased on day 7 of admission to the SICU. In accordance with increased urinary 4-PA level on day 7, the percentage of deficient urinary 4-PA level decreased from 25% on day 1 to zero on day 7. Unlike the results for plasma and erythrocyte PLP, serum and erythrocyte folate and serum vitamin B<sub>12</sub> concentrations significantly increased after a 7-day stay in the SICU. Only 4 patients had inadequate serum folate level on day 1, but no patients had deficient serum folate concentration on day 7 in the SICU. No patients had inadequate serum vitamin B<sub>12</sub> during the study period.</p>
</sec>
<sec id="section10-0884533612449654">
<title>Association Between Homocysteine and B Vitamins</title>
<p>Spearman partial correlation coefficients were performed to determine the association between plasma homocysteine and B vitamins after adjusting for age, sex, body weight, serum albumin, CRP, and CCR levels; results are shown in <xref ref-type="table" rid="table3-0884533612449654">Table 3</xref>. Only plasma and erythrocyte PLP concentrations on day 1 were adversely associated with day 1 levels of plasma homocysteine. Folate and vitamin B<sub>12</sub> status was not correlated with plasma homocysteine during the study period.</p>
<table-wrap id="table3-0884533612449654" position="float">
<label>Table 3.</label>
<caption><p>Spearman Partial Correlations Between Plasma Homocysteine and B Vitamins</p></caption>
<graphic alternate-form-of="table3-0884533612449654" xlink:href="10.1177_0884533612449654-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">Homocysteine, µmol/L (n = 32)<hr/></th>
</tr>
<tr>
<th/>
<th align="center">Day 1</th>
<th align="center">Δ (Day 7 – Day 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma PLP, nmol/L</td>
<td/>
<td/>
</tr>
<tr>
<td> Day 1</td>
<td>−0.48<xref ref-type="table-fn" rid="table-fn7-0884533612449654">*</xref></td>
<td>0.21</td>
</tr>
<tr>
<td> Δ (day 7 – day 1)</td>
<td/>
<td>0.49<xref ref-type="table-fn" rid="table-fn7-0884533612449654">*</xref></td>
</tr>
<tr>
<td colspan="3">Erythrocyte PLP, nmol/L</td>
</tr>
<tr>
<td> Day 1</td>
<td>−0.59<xref ref-type="table-fn" rid="table-fn7-0884533612449654">**</xref></td>
<td>−0.03</td>
</tr>
<tr>
<td> Δ (day 7 – day 1)</td>
<td/>
<td>0.22</td>
</tr>
<tr>
<td colspan="3">Erythrocyte PLP, pmol/g Hb</td>
</tr>
<tr>
<td> Day 1</td>
<td>−0.41<xref ref-type="table-fn" rid="table-fn7-0884533612449654">*</xref></td>
<td>0.11</td>
</tr>
<tr>
<td> Δ (day 7 – day 1)</td>
<td/>
<td>0.36</td>
</tr>
<tr>
<td colspan="3">Urinary 4-PA, µmol/d</td>
</tr>
<tr>
<td> Day 1</td>
<td>−0.40</td>
<td>−0.05</td>
</tr>
<tr>
<td> Δ (day 7 – day 1)</td>
<td/>
<td>0.03</td>
</tr>
<tr>
<td colspan="3">Serum folate, nmol/L</td>
</tr>
<tr>
<td> Day 1</td>
<td>−0.27</td>
<td>0.17</td>
</tr>
<tr>
<td> Δ (day 7 – day 1)</td>
<td/>
<td>0.14</td>
</tr>
<tr>
<td colspan="3">Erythrocyte folate, nmol/L</td>
</tr>
<tr>
<td> Day 1</td>
<td>−0.22</td>
<td>−0.13</td>
</tr>
<tr>
<td> Δ (day 7 – day 1)</td>
<td/>
<td>0.12</td>
</tr>
<tr>
<td colspan="3">Erythrocyte folate, nmol/g Hb</td>
</tr>
<tr>
<td> Day 1</td>
<td>−0.13</td>
<td>−0.24</td>
</tr>
<tr>
<td> Δ (day 7 – day 1)</td>
<td/>
<td>0.20</td>
</tr>
<tr>
<td>Serum vitamin B<sub>12</sub>, pmol/L</td>
<td/>
<td/>
</tr>
<tr>
<td> Day 1</td>
<td>−0.31</td>
<td>−0.13</td>
</tr>
<tr>
<td> Δ (day 7 – day 1)</td>
<td/>
<td>0.12</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0884533612449654">
<p>Values are presented as correlation coefficient (<italic>r</italic><sub><italic>s</italic></sub>) by using Spearman partial correlation coefficient after adjusting age, sex, body weight, serum albumin, C-reactive protein, and creatinine clearance rate. 4-PA, 4-pyridoxic acid; PLP, pyridoxal 5′-phosphate. Δ (day 7 – day 1) is the value of the difference between day 7 and day 1.</p>
</fn>
<fn id="table-fn7-0884533612449654">
<label>*</label>
<p><italic>P</italic> &lt; .05. **<italic>P</italic> &lt; .01.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-0884533612449654">
<title>Association Between Homocysteine and Clinical Outcomes</title>
<p>Plasma homocysteine concentration on day 1 or changes (Δ day 7 – day 1) did not show any association with clinical outcomes (ie, APACHE II score, length of ventilator dependency, ICU stay, and hospital stay) with or without adjusting for age, sex, body weight, serum albumin, CRP, and CCR levels (data not shown).</p>
</sec>
</sec>
<sec id="section12-0884533612449654" sec-type="discussion">
<title>Discussion</title>
<p>In the past few decades, not much attention has been paid to the prevalence of hyperhomocysteinemia in the critical care setting. In 2000, Schindler et al<sup><xref ref-type="bibr" rid="bibr14-0884533612449654">14</xref></sup> were the first to indicate that some critically ill patients (16% in their report) have hyperhomocysteinemia (plasma homocysteine concentration &gt;15 µmol/L). Eight years later, a 55% prevalence of hyperhomocysteinemia (plasma homocysteine concentration &gt;12 µmol/L) in ICU patients was reported by Abilés et al.<sup><xref ref-type="bibr" rid="bibr15-0884533612449654">15</xref></sup> In a recent study, there was a 12% prevalence of hyperhomocysteinemia (plasma homocysteine concentration &gt;15 µmol/L) in patients with sepsis.<sup><xref ref-type="bibr" rid="bibr23-0884533612449654">23</xref></sup> To make the comparison with the previous studies, we used 2 cutoff points (plasma homocysteine concentration ≥12 or ≥15 µmol/L) to define hyperhomocysteinemia in our study and observed that either 46.9% or 31.3% patients suffered from hyperhomocysteinemia on day 1 in the SICU, respectively. It is worth noting that the hyperhomocysteinemic condition was even worse after 7 days in the ICU. It seems that a high prevalence of hyperhomocysteinemia is still a serious problem in critically ill patients at admission.</p>
<p>Many factors are associated with hyperhomocysteinemia, in particular, deficiencies of folate, vitamin B<sub>12</sub>, and vitamin B<sub>6</sub> that are required for homocysteine metabolism. However, Schindler et al<sup><xref ref-type="bibr" rid="bibr14-0884533612449654">14</xref></sup> indicated that levels of B vitamins were not the potential determinants of plasma homocysteine concentration in their critically ill patients. Abilés et al<sup><xref ref-type="bibr" rid="bibr15-0884533612449654">15</xref></sup> indicated that critically ill patients who have adequate vitamin B<sub>12</sub> and folic acid intakes may also have lower plasma homocysteine levels. Although vitamin intake and concentrations were not monitoried in the study by Ploder et al,<sup><xref ref-type="bibr" rid="bibr23-0884533612449654">23</xref></sup> the authors postulated that adequate B vitamin supply from standard EN and vitamin supplementation would be unlikely to cause hyperhomocysteinemia in patients with sepsis. All of our patients received nutrition support (without vitamin supplementation), and almost none of our patients had inadequate folate and vitamin B<sub>12</sub> status; this might be why these 2 vitamins had no effect on their plasma homocysteine levels. With respect to the 3 B vitamins, data on folate and vitamin B<sub>12</sub> status in critically ill patients are scant. Vitamin B<sub>12</sub> deficiency does not seem to be a concern in the ICU.<sup><xref ref-type="bibr" rid="bibr10-0884533612449654">10</xref>,<xref ref-type="bibr" rid="bibr24-0884533612449654">24</xref>,<xref ref-type="bibr" rid="bibr25-0884533612449654">25</xref></sup> However, a much higher percentage of critically ill patients had inadequate vitamin B<sub>6</sub> status in the present study even though they received nutrition support. In addition, it was interesting to find that plasma and erythrocyte PLP remained constant even though vitamin B<sub>6</sub> intake significantly increased on day 7 of admission to the SICU. This was similar to the finding in our previous studies<sup><xref ref-type="bibr" rid="bibr12-0884533612449654">12</xref>,<xref ref-type="bibr" rid="bibr26-0884533612449654">26</xref></sup> and in other studies,<sup><xref ref-type="bibr" rid="bibr27-0884533612449654">27</xref></sup> and the mean plasma PLP concentration significantly decreased even though vitamin B<sub>6</sub> intake significantly increased during the study period. Friso et al<sup><xref ref-type="bibr" rid="bibr28-0884533612449654">28</xref></sup> have indicated that PLP acts as a coenzyme for the production of cytokines and other polypeptide mediators during the inflammatory response. It seems reasonable to conclude that the utilization and metabolic turnover of vitamin B<sub>6</sub> would be increased and the body pool of vitamin B<sub>6</sub> would be decreased during severe stress, inflammation, and severity of illness in critically ill patients; therefore, vitamin B<sub>6</sub> would be the major determinant of plasma homocysteine concentation in critically ill patients. Urinary 4-PA excretion is the metabolic end product of vitamin B<sub>6</sub> and is reflective of and influenced by recent vitamin B<sub>6</sub> intake.<sup><xref ref-type="bibr" rid="bibr22-0884533612449654">22</xref></sup> As vitamin B<sub>6</sub> intake increased and plasma and erythrocyte PLP remained unchanged on day 7 of admission, we noticed that urinary 4-PA concentration significantly increased on day 7 of admission. This might confirm the hypothesis that critically ill patients would use more plasma PLP and thus would excrete more 4-PA in urine. We previously administered a large dose supplement of vitamin B<sub>6</sub> (50 mg or 100 mg/d) to critically ill patients and observed that it could compensate for the lack of responsiveness of plasma PLP to vitamin B<sub>6</sub> intake.<sup><xref ref-type="bibr" rid="bibr29-0884533612449654">29</xref></sup> Further study could be done to clarify whether large-dose vitamin B<sub>6</sub> supplementation would also decrease plasma homocysteine concentration in critically ill patients.</p>
<p>Hyperhomocysteinemia has been shown to cause the overproduction of oxygen free radicals,<sup><xref ref-type="bibr" rid="bibr5-0884533612449654">5</xref></sup> the increase of inflammatory responses,<sup><xref ref-type="bibr" rid="bibr6-0884533612449654">6</xref>,<xref ref-type="bibr" rid="bibr7-0884533612449654">7</xref></sup> the enhancement of coagulation,<sup><xref ref-type="bibr" rid="bibr30-0884533612449654">30</xref>,<xref ref-type="bibr" rid="bibr31-0884533612449654">31</xref></sup> and the initiation of vascular smooth muscle cell proliferation,<sup><xref ref-type="bibr" rid="bibr32-0884533612449654">32</xref>,<xref ref-type="bibr" rid="bibr33-0884533612449654">33</xref></sup> which may further cause a higher oxidative stress and a lower total antioxidant capacity,<sup><xref ref-type="bibr" rid="bibr15-0884533612449654">15</xref></sup> especially in critically ill patients who are under particularly severe stress and have persistent inflammation. Therefore, the possible adverse effect of hyperhomocysteinemia on clinical outcomes is a cause for great concern. In agreement with previous results,<sup><xref ref-type="bibr" rid="bibr14-0884533612449654">14</xref>,<xref ref-type="bibr" rid="bibr34-0884533612449654">34</xref>,<xref ref-type="bibr" rid="bibr35-0884533612449654">35</xref></sup> our findings showed there was no association between plasma homocysteine concentration and clinical outcomes. Our critically ill patients had a stable clinical condition (a slightly increased APACHE II score on day 7 after admission) during the study period, and none of our patients suffered from severe hyperhomocysteinemia (plasma homocysteine &gt;100 µmol/L); this might account for the lack of association between clinical outcomes and plasma homocysteine concentration. However, the effect of plasma homocysteine concentration on clinical outcomes needs further study.</p>
<p>There were some limitations in this study. Although we calculated the sample size to meet the statistical power criteria, the loss of 21 patients from the study population might have decreased the significance of the associations between plasma homocysteine and the other 2 B vitamin indicators. The recruitment of a large sample population in the critical setting is a continuing challenge due to patients’ or their relatives’ reluctance to give consent to participate or patients’ severe clinical condition. The other limitation was that we measured only clinical and biochemical variables at admission and on day 7 of admission to the SICU. Greater observational frequency and a longer study period might provide a much clearer insight into the association between B vitamins and plasma homocysteine in critically ill patients. Another limitation was that the sepsis-related organ failure assessment (SOFA) score was not evaluated in our patients while they stayed in the SICU, and thus the interday comparison of severity of illness could not be determined.</p>
<p>In conclusion, among B vitamins (vitamin B<sub>6</sub>, folate, and vitamin B<sub>12</sub>), plasma homocysteine is associated only with vitamin B<sub>6</sub> status. Lower plasma PLP might be a significant factor contributing to increased plasma homocysteine concentration in critically ill surgical patients. Further research is warranted to investigate whether vitamin B<sub>6</sub> supplementation in critically ill surgical patients decreases their plasma homocysteine concentration. Although a high prevalence of hyperhomocysteinemia exists in the SICU, the association between plasma homocysteine and clinical outcomes was not found. The clinical impacts of hyperhomocysteinemia remain to be elucidated.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: This study was supported by Changhua Cristian Hospital and Chung Shan Medical University (97-CCH-CSHAN-07), Taiwan.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0884533612449654">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stipanuk</surname><given-names>MH</given-names></name>
</person-group>. <article-title>Metabolism of sulfur-containing amino acids</article-title>. <source>Annu Rev Nutr</source>. <year>1986</year>;<volume>6</volume>:<fpage>179</fpage>-<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr2-0884533612449654">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wald</surname><given-names>DS</given-names></name>
<name><surname>Law</surname><given-names>M</given-names></name>
<name><surname>Morris</surname><given-names>JK</given-names></name>
</person-group>. <article-title>Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis</article-title>. <source>BMJ</source>. <year>2002</year>;<volume>325</volume>:<fpage>1202</fpage>-<lpage>1208</lpage>.</citation>
</ref>
<ref id="bibr3-0884533612449654">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vasan</surname><given-names>RS</given-names></name>
<name><surname>Beiser</surname><given-names>A</given-names></name>
<name><surname>D’Agostino</surname><given-names>RB</given-names></name><etal/>
</person-group>. <article-title>Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction</article-title>. <source>JAMA</source>. <year>2003</year>;<volume>289</volume>:<fpage>1251</fpage>-<lpage>1257</lpage>.</citation>
</ref>
<ref id="bibr4-0884533612449654">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Finch</surname><given-names>JM</given-names></name>
<name><surname>Joseph</surname><given-names>J</given-names></name>
</person-group>. <article-title>Homocysteine, cardiovascular inflammation, and myocardial remodelling</article-title>. <source>Cardiovasc Hematol Disord Drug Targets</source>. <year>2010</year>;<volume>10</volume>:<fpage>241</fpage>-<lpage>245</lpage>.</citation>
</ref>
<ref id="bibr5-0884533612449654">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname><given-names>LL</given-names></name>
<name><surname>Wu</surname><given-names>JT</given-names></name>
</person-group>. <article-title>Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker</article-title>. <source>Clin Chim Acta</source>. <year>2002</year>;<volume>322</volume>:<fpage>21</fpage>-<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr6-0884533612449654">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rohde</surname><given-names>LE</given-names></name>
<name><surname>Hennekens</surname><given-names>CH</given-names></name>
<name><surname>Ridker</surname><given-names>PM</given-names></name>
</person-group>. <article-title>Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men</article-title>. <source>Am J Cardiol</source>. <year>1999</year>;<volume>84</volume>:<fpage>1018</fpage>-<lpage>1022</lpage>.</citation>
</ref>
<ref id="bibr7-0884533612449654">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gori</surname><given-names>AM</given-names></name>
<name><surname>Corsi</surname><given-names>AM</given-names></name>
<name><surname>Fedi</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>A proinflammatory state is associated with hyperhomocysteinemia in the elderly</article-title>. <source>Am J Clin Nutr</source>. <year>2005</year>;<volume>82</volume>: <fpage>335</fpage>-<lpage>341</lpage>.</citation>
</ref>
<ref id="bibr8-0884533612449654">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Potera</surname><given-names>C</given-names></name>
<name><surname>Rose</surname><given-names>DP</given-names></name>
<name><surname>Brown</surname><given-names>RR</given-names></name>
</person-group>. <article-title>Vitamin B6 deficiency in cancer patients</article-title>. <source>Am J Clin Nutr</source>. <year>1977</year>;<volume>30</volume>:<fpage>1677</fpage>-<lpage>1679</lpage>.</citation>
</ref>
<ref id="bibr9-0884533612449654">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vir</surname><given-names>SC</given-names></name>
<name><surname>Love</surname><given-names>AHG</given-names></name>
</person-group>. <article-title>Vitamin B6 status of the hospitalized aged</article-title>. <source>Am J Clin Nutr</source>. <year>1978</year>;<volume>31</volume>:<fpage>1383</fpage>-<lpage>1391</lpage>.</citation>
</ref>
<ref id="bibr10-0884533612449654">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Louw</surname><given-names>JA</given-names></name>
<name><surname>Werbeck</surname><given-names>A</given-names></name>
<name><surname>Louw</surname><given-names>MEJ</given-names></name>
<name><surname>Kotze</surname><given-names>TJ</given-names></name>
<name><surname>Cooper</surname><given-names>R</given-names></name>
<name><surname>Labadarios</surname><given-names>D</given-names></name>
</person-group>. <article-title>Blood vitamin concentrations during the acute-phase response</article-title>. <source>Crit Care Med</source>. <year>1992</year>;<volume>20</volume>:<fpage>934</fpage>-<lpage>941</lpage>.</citation>
</ref>
<ref id="bibr11-0884533612449654">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pfitzenmeyer</surname><given-names>P</given-names></name>
<name><surname>Guilland</surname><given-names>JC</given-names></name>
<name><surname>d’Athis</surname><given-names>P</given-names></name>
</person-group>. <article-title>Vitamin B6 and vitamin C status in elderly patients with infections during hospitalization</article-title>. <source>Ann Nutr Metab</source>. <year>1997</year>;<volume>41</volume>:<fpage>344</fpage>-<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr12-0884533612449654">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname><given-names>YC</given-names></name>
<name><surname>Lan</surname><given-names>PH</given-names></name>
<name><surname>Cheng</surname><given-names>CH</given-names></name>
<name><surname>Lee</surname><given-names>BJ</given-names></name>
<name><surname>Kan</surname><given-names>MN</given-names></name>
</person-group>. <article-title>Vitamin B6 intakes and status of mechanically ventilated critically ill patients in Taiwan</article-title>. <source>Eur J Clin Nutr</source>. <year>2002</year>;<volume>56</volume>:<fpage>387</fpage>-<lpage>392</lpage>.</citation>
</ref>
<ref id="bibr13-0884533612449654">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tal</surname><given-names>S</given-names></name>
<name><surname>Shavit</surname><given-names>Y</given-names></name>
<name><surname>Stern</surname><given-names>F</given-names></name>
<name><surname>Malnick</surname><given-names>S</given-names></name>
</person-group>. <article-title>Association between vitamin B12 levels and mortality in hospitalized older patients</article-title>. <source>J Am Geriatr Soc</source>. <year>2010</year>;<volume>58</volume>:<fpage>523</fpage>-<lpage>526</lpage>.</citation>
</ref>
<ref id="bibr14-0884533612449654">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schindler</surname><given-names>K</given-names></name>
<name><surname>Zauner</surname><given-names>C</given-names></name>
<name><surname>Buchmayer</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>High prevalence of hyperhomocysteinemia in critically ill patients</article-title>. <source>Crit Care Med</source>. <year>2000</year>;<volume>28</volume>:<fpage>991</fpage>-<lpage>995</lpage>.</citation>
</ref>
<ref id="bibr15-0884533612449654">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abilés</surname><given-names>J</given-names></name>
<name><surname>Abúd</surname><given-names>RP</given-names></name>
<name><surname>Moratalla</surname><given-names>G</given-names></name><etal/>
</person-group>. <article-title>High prevalence of hyperhomocysteinemia in critically ill patients: vascular damage and adequate vitamin intake</article-title>. <source>e-SPEN</source>. <year>2008</year>;<volume>3</volume>:<fpage>e240</fpage>-<lpage>e245</lpage>.</citation>
</ref>
<ref id="bibr16-0884533612449654">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Araki</surname><given-names>A</given-names></name>
<name><surname>Sako</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Determination of free and total homocysteine in human plasma by high performance liquid chromatography with fluorescence detection</article-title>. <source>J Chromatogr</source>. <year>1987</year>;<volume>422</volume>:<fpage>43</fpage>-<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr17-0884533612449654">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Radha Rama Devi</surname><given-names>A</given-names></name>
<name><surname>Naushad</surname><given-names>SM</given-names></name>
<name><surname>Prasad</surname><given-names>KC</given-names></name>
</person-group>. <article-title>Evaluation of total plasma homocysteine in Indian newborns using heel-prick samples</article-title>. <source>Indian J Pediatr</source>. <year>2006</year>;<volume>73</volume>:<fpage>503</fpage>-<lpage>508</lpage>.</citation>
</ref>
<ref id="bibr18-0884533612449654">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Talwar</surname><given-names>D</given-names></name>
<name><surname>Quasim</surname><given-names>T</given-names></name>
<name><surname>McMillan</surname><given-names>DC</given-names></name>
<name><surname>Kinsella</surname><given-names>J</given-names></name>
<name><surname>Williamson</surname><given-names>C</given-names></name>
<name><surname>O’Reilly</surname><given-names>DS</given-names></name>
</person-group>. <article-title>Optimisation and validation of a sensitive high-performance liquid chromatography assay for routine measurement of pyridoxal 5-phosphate in human plasma and red cells using pre-column semicarbazide derivatisation</article-title>. <source>J Chromatogr B</source>. <year>2003</year>;<volume>792</volume>:<fpage>331</fpage>-<lpage>341</lpage>.</citation>
</ref>
<ref id="bibr19-0884533612449654">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gregory</surname><given-names>JF</given-names><suffix>III</suffix></name>
<name><surname>Kirk</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Determination of urinary 4-pyridoxic acid using high performance liquid chromatography</article-title>. <source>Am J Clin Nutr</source>. <year>1979</year>;<volume>32</volume>: <fpage>879</fpage>-<lpage>883</lpage>.</citation>
</ref>
<ref id="bibr20-0884533612449654">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jacobsen</surname><given-names>D</given-names></name>
</person-group>. <article-title>Determinants of hyperhomocysteinemia: a matter of nature or nurture</article-title>. <source>Am J Clin Nutr</source>. <year>1996</year>;<volume>64</volume>:<fpage>641</fpage>-<lpage>642</lpage>.</citation>
</ref>
<ref id="bibr21-0884533612449654">
<label>21.</label>
<citation citation-type="book">
<collab>Food and Nutrition Board, Institute of Medicine</collab>. <source>Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B-6, Folate, Vitamin B-12, Pantothenic Acid, Biotin, and Choline</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academies Press</publisher-name>; <year>1998</year>.</citation>
</ref>
<ref id="bibr22-0884533612449654">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leklem</surname><given-names>JE</given-names></name>
</person-group>. <article-title>Vitamin B6: a status report</article-title>. <source>J Nutr</source>. <year>1990</year>;<volume>120</volume>:<fpage>1503</fpage>-<lpage>1507</lpage>.</citation>
</ref>
<ref id="bibr23-0884533612449654">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ploder</surname><given-names>M</given-names></name>
<name><surname>Kurz</surname><given-names>K</given-names></name>
<name><surname>Spittler</surname><given-names>A</given-names></name>
<name><surname>Neurauter</surname><given-names>G</given-names></name>
<name><surname>Roth</surname><given-names>E</given-names></name>
<name><surname>Fuchs</surname><given-names>D</given-names></name>
</person-group>. <article-title>Early increase of plasma homocysteine in sepsis patients with poor outcome</article-title>. <source>Mol Med</source>. <year>2010</year>;<volume>16</volume>:<fpage>498</fpage>-<lpage>504</lpage>.</citation>
</ref>
<ref id="bibr24-0884533612449654">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Galloway</surname><given-names>P</given-names></name>
<name><surname>McMillan</surname><given-names>DC</given-names></name>
<name><surname>Sattar</surname><given-names>N</given-names></name>
</person-group>. <article-title>Effect of the inflammatory response on trace element and vitamin status</article-title>. <source>Ann Clin Biochem</source>. <year>2000</year>;<volume>37</volume>:<fpage>289</fpage>-<lpage>297</lpage>.</citation>
</ref>
<ref id="bibr25-0884533612449654">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manzanaresa</surname><given-names>W</given-names></name>
<name><surname>Hardy</surname><given-names>G</given-names></name>
</person-group>. <article-title>Vitamin B12: the forgotten micronutrient for critical care</article-title>. <source>Curr Opin Clin Nutr Metab Care</source>. <year>2010</year>;<volume>13</volume>:<fpage>662</fpage>-<lpage>668</lpage>.</citation>
</ref>
<ref id="bibr26-0884533612449654">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname><given-names>YC</given-names></name>
<name><surname>Chang</surname><given-names>HH</given-names></name>
<name><surname>Huang</surname><given-names>SC</given-names></name><etal/>
</person-group>. <article-title>Plasma pyridoxal 5′-phosphate is a significant indicator of immune responses in the mechanically ventilated critically ill</article-title>. <source>Nutrition</source>. <year>2005</year>;<volume>21</volume>:<fpage>779</fpage>-<lpage>785</lpage>.</citation>
</ref>
<ref id="bibr27-0884533612449654">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Powers</surname><given-names>JS</given-names></name>
<name><surname>Zimmer</surname><given-names>J</given-names></name>
<name><surname>Meurer</surname><given-names>K</given-names></name>
<name><surname>Manske</surname><given-names>E</given-names></name>
<name><surname>Collins</surname><given-names>JC</given-names></name>
<name><surname>Greene</surname><given-names>HL</given-names></name>
</person-group>. <article-title>Direct assay of vitamins B1, B2, and B6 in hospitalized patients: relationship to level of intake</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1993</year>;<volume>17</volume>:<fpage>315</fpage>-<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr28-0884533612449654">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Friso</surname><given-names>S</given-names></name>
<name><surname>Jacques</surname><given-names>PF</given-names></name>
<name><surname>Wilson</surname><given-names>PWF</given-names></name>
<name><surname>Rosenberg</surname><given-names>IH</given-names></name>
<name><surname>Selhub</surname><given-names>J</given-names></name>
</person-group>. <article-title>Low circulating vitamin B<sub>6</sub> is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>103</volume>:<fpage>2788</fpage>-<lpage>2791</lpage>.</citation>
</ref>
<ref id="bibr29-0884533612449654">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>CH</given-names></name>
<name><surname>Huang</surname><given-names>YC</given-names></name>
<name><surname>Chang</surname><given-names>SJ</given-names></name>
<name><surname>Lee</surname><given-names>BJ</given-names></name>
<name><surname>Lin</surname><given-names>KL</given-names></name>
</person-group>. <article-title>Vitamin B<sub>6</sub> supplementation improves immune responses in critically ill patients</article-title>. <source>Eur J Clin Nutr</source>. <year>2006</year>;<volume>60</volume>:<fpage>1207</fpage>-<lpage>1213</lpage>.</citation>
</ref>
<ref id="bibr30-0884533612449654">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harpel</surname><given-names>PC</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
<name><surname>Borth</surname><given-names>W</given-names></name>
</person-group>. <article-title>Homocysteine and hemostasis: pathogenetic mechanism predisposing to thrombosis</article-title>. <source>J Nutr</source>. <year>1996</year>;<volume>126</volume>:<fpage>1285s</fpage>-<lpage>1289s</lpage>.</citation>
</ref>
<ref id="bibr31-0884533612449654">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eldibany</surname><given-names>ME</given-names></name>
<name><surname>Caprini</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Hyperhomocysteinemia and thrombosis: an overview</article-title>. <source>Arch Pathol Lab Med</source>. <year>2007</year>;<volume>131</volume>:<fpage>872</fpage>-<lpage>884</lpage>.</citation>
</ref>
<ref id="bibr32-0884533612449654">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsai</surname><given-names>JC</given-names></name>
<name><surname>Wang</surname><given-names>H</given-names></name>
<name><surname>Perrella</surname><given-names>MA</given-names></name><etal/>
</person-group>. <article-title>Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells</article-title>. <source>J Clin Invest</source>. <year>1996</year>;<volume>97</volume>:<fpage>146</fpage>-<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr33-0884533612449654">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>C</given-names></name>
<name><surname>Halkos</surname><given-names>ME</given-names></name>
<name><surname>Surowiec</surname><given-names>SM</given-names></name>
<name><surname>Conklin</surname><given-names>BS</given-names></name>
<name><surname>Lin</surname><given-names>PH</given-names></name>
<name><surname>Lumsden</surname><given-names>AB</given-names></name>
</person-group>. <article-title>Effects of homocysteine on smooth muscle cell proliferation in both cell culture and artery perfusion culture models</article-title>. <source>J Surg Res</source>. <year>2000</year>;<volume>88</volume>:<fpage>26</fpage>-<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr34-0884533612449654">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsangaris</surname><given-names>I</given-names></name>
<name><surname>Tsantes</surname><given-names>A</given-names></name>
<name><surname>Bagos</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>The effect of plasma homocysteine levels on clinical outcomes of patients with acute lung injury/acute respiratory distress syndrome</article-title>. <source>Am J Med Sci</source>. <year>2009</year>;<volume>338</volume>:<fpage>474</fpage>-<lpage>477</lpage>.</citation>
</ref>
<ref id="bibr35-0884533612449654">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsantes</surname><given-names>A</given-names></name>
<name><surname>Tsangaris</surname><given-names>I</given-names></name>
<name><surname>Nikolopoulos</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>The effect of homocysteine on the clinical outcomes of ventilated patients with severe sepsis</article-title>. <source>Minerva Anestesiol</source>. <year>2010</year>;<volume>76</volume>:<fpage>787</fpage>-<lpage>794</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>